Showing 6481-6490 of 7932 results for "".
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- High Kissability Marks for Restylane Kysse in New Phase 4 Studyhttps://practicaldermatology.com/news/high-kissability-marks-for-restylane-kysse-in-new-phase-4-study/2460465/In a recent first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, subject satisfaction as well as partner satisfaction were evaluated following treatment with Restylane Kysse. Many consumers report they often keep their lip treatments a
- Cutera Launches Fraxis PROhttps://practicaldermatology.com/news/cutera-launches-fraxis-pro/2460464/Cutera, Inc. is launching Fraxis PRO progressive dermal remodeling technology. Fraxis PRO combines fractional CO2 for skin resurfacing and radiofrequency microneedling for dermal remodeling in a single device. Fraxis PRO treats: Fine Lines
- Azitra Awarded Patent for Engineered Bacterial Strain Discovery Platformhttps://practicaldermatology.com/news/azitra-awarded-patent-for-engineered-bacterial-strain-discovery-platform/2460463/Azitra, Inc. has been issued a patent for the company’s engineered bacterial strain discovery platform. The United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,702,558, which includes broad composition of matter claims that are central to the the company’s pr
- Allergan Helps Bridge the Gender Gap in STEMhttps://practicaldermatology.com/news/allergan-helps-bridge-the-gender-gap-in-stem/2460460/Allergan has pledged $300K to support STEM Education through their partnership with Girls Inc. In addition to the donation, Allergan is also offering mentoring initiatives and resources to educate and emp
- Evolus Loses Round 1 in Trade Battle with AbbVie's Allerganhttps://practicaldermatology.com/news/evolus-loses-round-1-in-trade-battle-with-abbvies-allergan/2460455/Evolus' and Daewoong Pharma's Jeuveau lost the first round in a trade dispute with AbbVie's Allergan and its Korean partner Medytox that sought to block imports of the Botox rival, but the match is not over yet. AbbVie's Allergan and its Korean partner Medytox
- Soliton Seeks 510k Clearance for RAP Anti-Cellulite Devicehttps://practicaldermatology.com/news/soliton-seeks-510-clearance-for-rap-anti-cellulite-device/2460452/Soliton, Inc. filed for 510(k) premarket clearance with the U.S. Food and Drug Administration (FDA) of its second-generation Rapid Acoustic Pulse (RAP) device for the reduction in the appearance of cellulite. The RAP device was previously cleared by the FDA as an accessory to a 1064 nm
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operati
- Ortho Dermatologics Launches Arazlo Lotion in the UShttps://practicaldermatology.com/news/ortho-dermatologics-launches-arazlo-lotion-in-the-us/2460447/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics launched Arazlo (tazarotene) Lotion, 0.045%. Now available commercially to health care professionals in the US, it was FDA approved in December 2019 as the first tazaroten
- Arcutis: Enrollment Complete for Phase 2 Study of Roflumilasthttps://practicaldermatology.com/news/arcutis-enrollment-complete-for-phase-2-study-of-roflumilast/2460446/Enrollment is now complete for the Phase 2 proof of concept clinical trial evaluating roflumilast foam for the treatment of seborrheic dermatitis. Arcutis Biotherapeutics is developing roflumilast, a selective phosphodiesterase type 4 inhibitor (PDE4 inhibitor), in a once-daily topical